Clinical Trials: Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines

Sponsor and Collaborators

National Cancer Institute (NCI)

Contact

Recruitment Center – SB

866-820-4505

[email protected]

Principal Investigator

None indicated

ClinicalTrials.gov Identifier

NCT00923195